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Abstract
Background: Males lose more handgrip strength (HGS) than females when adductor pollicis (AP) TOF ratio decreases. The reason
is unclear.
Objectives: The primary aim of this study was to explore gender-related differences in neuromuscular sensitivity to mivacurium.
As a secondary aim, clearance of mivacurium was determined.
Methods: In 10 healthy males and 10 healthy females, constant-rate infusions of mivacurium were administered to obtain three
different levels of stable neuromuscular block (normalized acceleromyography AP TOF ratio 80, 60, and 40%) in each study subject.
Arterial blood samples were collected to determine mivacurium plasma concentrations. The HGS was measured every five minutes.
A Hill equation was fitted to data on mivacurium concentration versus normalized AP TOF ratio and HGS to determine drug con-
centrations associated with 50% maximum effect (C50 AP TOF ratio and C50 HGS). Differences within and between genders were
tested with the parametric t-test. Clearance of mivacurium was calculated at each block level as the ratio between drug infusion
rate and concentration. Gender-related differences in relationships between AP TOF ratio and HGS, mivacurium infusion rates, and
mivacurium plasma concentrations were determined with linear mixed-models.
Results: The C50 AP TOF ratio was significantly greater than C50 HGS in males, yet not in females. Mivacurium infusion rates, needed
to maintain stable neuromuscular blocks, were significantly greater in males, while clearance was similar between genders. Males
lost significantly more HGS with decreasing AP TOF ratio than females, both in absolute (kg) and relative (percentage of baseline)
terms.
Conclusions: In males, yet not in females, the AP was significantly less sensitive to the effect of mivacurium than the muscles in-
volved in the handgrip function. This finding explains why handgrip strength decreases more in males than females with decreasing
AP TOF ratio during the mivacurium block.
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1. Background
In a previous study on healthy human volunteers, the
authors reported that males and females respond differ-
ently to mivacurium. As mivacurium dose was increased,
to render similar decreases in adductor pollicis (AP) train-
of-four (TOF) ratio in both genders, the reduction in ac-
tual handgrip strength (HGS) was greater in males. Males
also lost the ability to clench teeth, swallow, and raise their
head > 5 seconds at a higher TOF ratio than females (1).
In that study, all measurements were recorded under con-
ditions, where stable AP TOF ratios were meticulously es-
tablished. Consequently, although gender-related differ-
ences in pharmacokinetics of mivacurium may exist, they
cannot explain the findings. In the present investigation,
the authors sought to compare the pharmacodynamics of
mivacurium in males and females, in a population where
gender-related differences in the relationships between AP
TOF ratio and HGS were confirmed.
2. Objectives
The specific aims were to determine C50-values (2) for
AP TOF ratio and HGS, i.e. drug concentrations at steady
state conditions associated with 50% maximum effect (a
measure of drug sensitivity), and γ, the slope of the mi-
vacurium drug concentration versus effect curve. The re-
searchers hypothesized that the relationship between C50
AP TOF ratio and C50 HGS was different between males and
females.
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3. Methods
The study was an interventional clinical trial on
healthy volunteers.
3.1. Approvals
The study protocol conformed to the ethical guidelines
of the 1975 Declaration of Helsinki and approval was ob-
tained from the Institutional Review Board at the Univer-
sity of California in San Francisco (University of California
protocol record #IRB 11-07970). This investigation adhered
to the applicable equator guidelines and was registered
with ClinicalTrials.gov (NCT01906528, July 24, 2013).
3.2. Enrolment
Ten males (29± 7 years old, 76± 7 kg, and BMI: 23.1± 2)
and 10 females (26 ± 4 years old, 63 ± 9 kg, and BMI: 23.3
± 2) were included after an in-depth interview and writ-
ten consent was obtained from each study subject. Inclu-
sion criteria were being healthy, age of 18 to 40 years old,
and normal airway exam. Exclusion criteria were BMI >
25, smoking, medication interfering with neuromuscular
blocking drugs, history with anesthesia-related problems,
acid reflux, current upper airway infection, positive urine
pregnancy test, or breast feeding.
3.3. Administration of Mivacurium
Mivacurium, as the sole drug, was administered to-
gether with lactated Ringer’s solution via the antecubital
vein in the left arm, using a Harvard infusion pump (Har-
vard Clinical Technology, Inc. Natick, MA). The initial infu-
sion rates were 1.5 (males) and 1.2 (females)µg.kg-1.min-1 (3).
The infusion rate was changed (± 10% to 50%) twice to ob-
tain three levels of stable plasma concentrations.
3.4. Train-of-Four (TOF) Ratio Measurements
The TOF ratio was measured every 15 seconds at the
left AP muscle using acceleromyography (“TOF Watch SX”,
Merck Co., Whitehouse Station, NJ). A hand adapter (Merck
Co.) applying approximately 75 g preload to the thumb
was used to enhance repeatability of the measurements
(4). The signal from the monitor was analyzed using the
TOFMON software (Merck Co., Whitehouse Station, NJ). A
continuous moving average of four consecutive TOF ratios
was the value taken. The TOF ratio was considered stable if
the difference in average TOF ratios was < 3% over a period
of at least 10 minutes of continuous nerve stimulation.
The researchers believed that the volunteers would
not tolerate supramaximal nerve stimulation during each
study. The stimulating current was maintained at≥ 15 mA
above the threshold for detection of the twitch response
in order to obtain reliable recordings (5). The intensity of
nerve stimulation was transiently increased by 5 mA every
15 minutes in order to ensure the stability of the TOF re-
sponse. Hand skin temperature of > 32°C was maintained
with blankets.
Stable AP TOF ratios were targeted at three different lev-
els: AP TOF ratio approximately 0.8 (superficial), 0.6 (mod-
erate), and 0.4 (deep). In order to compensate for baseline
TOF ratios different from 100%, all values were normalized
by dividing each uncorrected TOF ratio with that subjects’
baseline value.
3.5. Recording of Handgrip Strength
Every five minutes, the handgrip strength of the right
hand was measured twice with a calibrated dynamometer
(Jamar 5030J1, Sammons Preston, Chicago, IL) (6). The aver-
age HGS-value at each level of stable neuromuscular block
was used in the pharmacodynamic analysis. All volunteers
familiarized themselves with the equipment before initia-
tion of each study.
3.6. Volunteer Safety Management
Two trained anesthesiologists were present at all times
during experiments, and electrocardiogram, heart rate,
non-invasive blood pressure, and arterial oxygen satura-
tion were monitored. Emergency equipment and drugs
were readily available.
As a safety measure during each study, the ability of the
volunteer to clench teeth and swallow was tested. Inabil-
ity to clench the teeth is an important predictor of reduc-
tion in upper airway patency (3, 7), and was tested by asking
the volunteers to retain a wooden tongue depressor placed
between the incisors, while the investigator attempted to
pull it out with the thumb and index finger (3). Swallowing
was tested by asking the volunteer to grade subjectively if it
was harder than normal to clear saliva from the throat, and
by checking the ability to drink water via a straw. Volun-
teers were considered unable to swallow if it was observed
that the study subject could not elevate the larynx (8).
In order to detect rapid functional changes during
non-steady state plasma concentrations of mivacurium, all
tests were performed every five minutes. Baseline evalua-
tions were obtained before commencement of the mivac-
urium infusion. All assessments were performed in the
supine position with the upper body elevated 15 degrees.
The following criteria indicated that the mivacurium
infusion had to be reduced or terminated immediately:
The volunteer asked to discontinue; signs of airway ob-
struction (stridor); complete loss of ability to swallow; or
arterial oxygen saturation below 90%.
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3.7. OutcomeMeasures
3.7.1. Primary: Pharmacodynamics
Differences between C50 AP TOF ratio and C50 HGS, and
between γ AP TOF ratio and γ HGS, within and between
genders.
3.7.2. Secondary: Clearance of Mivacurium




At each level of stable neuromuscular block, arterial
blood samples were collected via a catheter inserted in the
left radial artery to determine mivacurium plasma concen-
trations. Duplicate samples, 10 minutes apart were col-
lected to confirm stable plasma concentrations, and the
average value was reported. Overall, 5 mL of blood was
transferred to an EDTA-vacutainer containing 1.25 mg of
phospholine iodide (prevents mivacurium degradation).
Samples were centrifuged and plasma was frozen at -80 de-
grees for later analysis with mass spectrometry (6). The as-
say is sensitive to 5 ng.mL-1 with a coefficient of variation
of < 3.2% in the concentration range between 5 and 400
ng.mL-1.
3.8.2. Pharmacodynamic Analysis
C50 is the blood or plasma concentration at steady
state conditions, associated with 50% of maximum drug
effect, and it has been a long tradition in anesthesia liter-
ature to use this variable as a measure of drug sensitivity
(2). Using an iterative process (Solver function in Excel), a
Hill equation (Effect = Cγ /Cγ + Cγ50) was fitted to normal-
ized AP TOF ratio and HGS values versus corresponding mi-
vacurium plasma concentrations obtained at stable neu-
romuscular blocks, in order to estimate C50 AP TOF ratio
and C50 HGS in each study subject. The slope factor of the
concentration-effect curve (γAP TOF ratio and γHGS) was
estimated in the same process.
3.8.3. Drug Clearance
The plasma clearance of mivacurium was calculated at
each level of stable neuromuscular block as steady state
mivacurium infusion rate (µg.kg-1.min-1) divided by the mi-
vacurium plasma concentration (µg.mL-1).
3.9. Power Analysis
The researchers assumed that the same number of
study subjects were needed in the present as in the pre-
vious investigation (1). In that study, the power analysis
was based on data from a publication in 2010 (9), where
a difference of 20% in loss of HGS between males and fe-
males was observed. The interindividual standard devi-
ations (SD) were 7% (males) and 14% (females). A 5% er-
ror margin was added to compensate for the small num-
ber of study subjects (males 7 + 5% and females 14 + 5%).
With these assumptions, the power analysis showed that
20 study subjects had to be enrolled to detect a 20% dif-
ference with > 80% probability, assuming an α error of <
0.05.
3.10. Statistical Analysis
Groupwise comparisons were tested using the para-
metric t-test. The relationships between AP TOF ratio and
HGS, mivacurium infusion rates, and mivacurium con-
centrations were tested with least squares linear regres-
sion. The regressions were analyzed with a mixed-model
that accommodates dependencies in the observations and
compensates completely for repeated measurements. This
model used AP TOF ratio as a continuous variable and in-
cluded HGS, mivacurium infusion rates and concentra-
tions, gender, and the TOF ratio × gender interaction (in-
teraction term) as fixed effects, and individuals as random
effects. The significance level was set at P < 0.05. All statis-
tical analyses were made using JMP version 11.0 (SAS Insti-
tute, Cary, NC).
4. Results
Body weight was significantly greater in males than fe-
males (P < 0.001) yet age and BMI were similar (P < 0.85
and < 0.95). All study subjects completed the study. Eight
males and two females lost the ability to clench teeth,
while two males lost the ability to swallow at the deepest
level of neuromuscular block. Breathing problems or signs
of aspiration were not observed, and oxygen saturation
was never < 95% in any individual. Blurry vision occurred
as the first sign of neuromuscular blockade, and was the
last to disappear after conclusion of the experiment.
Slopes of the relationships between AP TOF ratio and
HGS were different between genders both in absolute (loss
of HGS in kg from baseline / % reduction in normalized
AP TOF ratio) and relative (% loss of HGS from baseline / %
reduction in normalized AP TOF ratio) terms (interaction
term: P < 0.001 and P = 0.003, respectively), confirming the
researchers’ previous findings (1) that the loss of handgrip
strength with decreasing AP TOF ratio is greater in males
than females (Table 1). The relationships between AP TOF
ratio and mivacurium infusion rate and concentration did
not differ between genders (Table 1).
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Loss of HGS (kg) vs. AP TOF ratiob 0.0080 ± 0.012 -0.0010 ± 0.016
Range -0.017 - 0.024 -0.0017 - 0.0013
95% CI 0.004 - 0.016 -0.0040 - 0.002
P value for TOF ratio × interactionc < 0.001
Loss of HGS (%) vs. AP TOF ratio 0.016 ± 0.020 -0.0045 ± 0.020
Range -0.030 - 0.038 -0.021 - 0.019
95% CI 0.002 - 0.030 -0.018 - 0.000
P value for TOF ratio × interactionc 0.003
Mivacurium infusion rate (µg.kg.min-1) vs. AP TOF ratio 0.024 ± 0.01 0.021 ± 0.01
Range 0.011 - 0.047 0.007 - 0.035
95% CI 0.018 - 0.030 0.015 - 0.027
P value for TOF ratio × interactionc 0.81
Mivacurium plasma concentration (µg.kg-1) vs. AP TOF ratio 0.66 ± 0.27 0.70 ± 0.24
Range 0.44 - 1.12 0.40 - 1.18
95% CI 0.50 - 0.82 0.55 - 0.85
P value for TOF ratio × interactionc 0.79
Abbreviation: 95% CI, 95% confidence interval.
aValues are expressed as mean ± SD unless otherwise indicated.
bLoss of AP TOF ratio (%), percentage loss of normalized adductor pollicis TOF ratio from baseline; Loss of HGS, absolute loss (kg) or percentage loss (%) of handgrip
strength from baseline.
cTOF ratio × interaction, the interaction term, showing the influence of sex on relationship.
4.1. Primary OutcomeMeasure: Pharmacodynamics
In males C50 AP TOF ratio (54.1± 12.0, CI: 44.1 - 62.2) was
significantly greater than C50 HGS (38.4±9.1, CI: 31.0 - 44.0)
(P = 0.007) (Figure 1). In females, C50 TOF ratio (44.4 ± 9.1,
CI: 37.7 - 51.6) was similar to C50 HGS (41.0 ± 6.2, CI: 36.1 -
45.1) (P = 0.35) (Figure 1). Accordingly, the calculated C50
AP TOF ratio - C50 HGS difference was significantly greater
in males than females (15.1 ± 10.0, CI: 8.0 - 21.1 versus 3.0 ±
8.1, CI: -2.3 - 8.0, P = 0.01) (Table 2). The C50 AP TOF ratio was
marginally greater in males than females (P = 0.07), while
C50 HGS was similar between genders (P = 0.45) (Table 2).
TheγTOF ratio andγHGS were similar within and between
genders (Table 2).
4.2. Secondary OutcomeMeasure: Clearance of Mivacurium
Mivacurium infusion rates were greater in males than
females at all levels of stable neuromuscular block (P <
0.001) (Table 3). The gender-related differences in mivac-
urium plasma concentrations reached a significance level
at the superficial and moderate block levels (P = 0.05 and
0.03), yet not at the deep block (P = 0.13) (Table 3). The cal-
culated clearance of mivacurium was similar in males and
females at all neuromuscular blocks (P = 0.32 to 0.45) (Table
3).
5. Discussion
5.1. Pharmacodynamics of Mivacurium
In the present study, where the gender-related differ-
ence in the relationship between AP TOF ratio and HGS was
confirmed (Table 1), differences in the pharmacodynamics
of mivacurium between males and females was demon-
strated. C50 AP TOF ratio was significantly greater than
C50 HGS only in males (Figure 1), and the calculated C50
AP TOF ratio - C50 HGS difference was five times greater
in males than females (P = 0.01, Table 2). These findings
adequately explain why males lose handgrip strength to a
greater extent than females when AP TOF ratio decreases.
It is likely that most of the observed gender-related differ-
ence is caused by C50 AP TOF ratio being greater in males
than females, although not unequivocally shown with the
current data (P = 0.07).
Previously, the current researchers showed that males
lose the ability to clench teeth, raise head > 5, and swal-
low at greater AP TOF ratios than females during mivac-
urium block (1). In addition, reexamination of data from
a study on pulmonary function during low-degree mivac-
urium block (9) showed that males also lost the ability to
perform vital capacity breathing at greater AP TOF ratios
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Figure 1. The graph shows the relationships between mivacurium steady state plasma concentrations (ng ml-1) and fractional changes in adductor pollicis train-of-four ratio
(AP TOF Ratio) and handgrip strength (HGS) in both sexes. The mivacurium concentration at fractional change 0.5 represents C50, i.e. the mivacurium concentration associated
with 50% of the maximum effect. C50 APTOF ratio is significantly greater than C50 HGS in males (P = 0.007). The C50 TOF ratio - C50 HGS difference is 5 times greater in males
than females (P = 0.01). Error bars (slightly offset) are 95% confidence interval of C50 AP TOF ratio and C50 HGS in male subjects. Of clarity reasons, confidence intervals are
not shown for female study subjects.
than females. These previous findings are consistent with
the assumption that in males a significant gap exists, not
only between C50 AP TOF ratio and C50 HGS, yet between
C50 AP TOF ratio and C50 of several other muscle groups
as well. The current authors infer that the observations
mirror gender-related differences in the functional rela-
tionship between the AP muscle and muscle groups rele-
vant for maintenance of a patent upper airway and normal
breathing ability during low-degree neuromuscular block
(i.e. AP TOF ratio in the range 40% - 80%).
5.2. Clearance of Mivacurium
In the authors’ previous study (1), potential differences
in pharmacokinetics of mivacurium could not explain the
finding that males lost relatively more handgrip strength
than females with decreasing AP TOF ratio, because mea-
surements were obtained at stable neuromuscular blocks.
However, the study design did not rule out the possibil-
ity that differences in pharmacokinetics of this drug exist
between genders. The authors, therefore, included deter-
mination of mivacurium clearance as a secondary aim of
the present investigation. The study design allowed calcu-
lations of mivacurium clearance at three different neuro-
muscular blocks in each study subject, and the results sug-
gest that mivacurium clearance is similar in males and fe-
males (Table 3). Gender-related differences in other phar-
macokinetic variables may exist, yet determination of a
complete pharmacokinetic profile of mivacurium was not
possible with the study design used in the current investi-
gation.
5.3. Clinical Implications
The current findings may have a bearing on the clin-
ical use of TOF monitoring. When neuromuscular func-
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Table 2. Pharmacodynamic Data for Mivacurium
Variable Males Females P Value (Males vs. Females)
C50 AP TOF ratio (ng.mL-1)a 54.1 ± 12.0 44.0 ± 9.1 0.07
Range 38.5 - 77.0 27.2 - 60.2
95% CI 44.1 - 62.2 37.7 - 51.6
γ AP TOF ratioa 4.0 ± 2.1 3.2 ± 1.1 0.38
Range 2.2 - 8.0 1.4 - 5.6
95% CI 2.4 - 5.2 2.1 - 4.1
C50 HGS (ng.mL-1)a 38.4 ± 9.1 41.0 ± 6.2 0.45
Range 29.0 - 60.5 29.5 - 54.1
95% CI 31.0 - 44.0 36.1 - 45.1
γ HGSa 4.2 ± 2.3 4.0 ± 1.3 0.60
Range 2.4 - 8.1 2.1 - 5.5
95% CI 2.2 - 5.2 2.2 - 4.2
C50 AP TOF ratio - C50 HGS difference (ng.mL-1)a 15.1 ± 10.0 3.0 ± 8.1 0.01
Range 1.2 - 35.1 -13.1 - 12.4
95% CI 8.0 - 21.1 -2.3 - 8.0
Abbreviations: AP TOF ratio, normalized TOF ratio at the adductor pollicis muscle; C50, plasma concentration at steady state associated with 50% of maximum effect;
HGS, handgrip strength; γ , slope of the drug concentration - effect curve; 95% CI, 95% Confidence Interval.
aValues are expressed as mean ± SD.
Table 3. Mivacurium Infusion Rate, Plasma Concentration, and Calculated Clearance at Three Levels of Stable Neuromuscular Blocks
Block Level
Superficial Moderate Deep
Males Females Males Females Males Females
Mivacurium infusion rate (µg.kg.min-1)a 1.46 ± 0.12 1.09 ± 0.19 1.96 ± 0.28 1.49 ± 0.18 2.29 ± 035 1.87 ± 0.22
Range 1.1 - 1.5 0.6 - 1.2 1.5 - 2.5 1.2 - 1.8 2.0 - 3.0 1.7 - 2.2
95% CI 1.37 - 1.54 0.95 - 1.22 1.75 - 2.16 1.36 - 1.61 2.03 - 2.54 1.71 - 2.02
P Value (males vs. females) < 0.001 < 0.001 < 0.001
Mivacurium plasma concentration (ng.mL-1)a 32.0 ± 6.1 28.2 ± 5.0 46.0 ± 7.8 38.2 ± 6.8 54.8 ± 7.0 51.0 ± 7.1
Range 17.4 - 39.2 21.4 - 36.6 32.4 - 58.1 27.8 - 50.9 40.0 - 65.7 39.0 - 63.3
95% CI 27.6 - 36.3 24.6 - 31.7 40.4 - 51.5 33.3 - 43.0 49.7 - 59.8 45.9 - 56.0
P Value (males vs. females) 0.05 0.03 0.13
Mivacurium clearance (mL.kg.min-1)a 43.0 ± 15.0 41.1 ± 10.0 43.1 ± 8.0 40.9 ± 7.0 42.1 ± 5.0 37.8 ± 5.0
Range 30.5 - 84.0 25.9 - 56.7 31.0 - 61.0 29.9 - 54.6 34.0 - 48.0 30.5 - 48.5
95% CI 38.0 - 58.0 34.1 - 46.0 35.0 - 51.0 36.1 - 47.2 37.0 - 47.0 33.5 - 43.5
P Value (males vs. females) 0.45 0.34 0.35
Abbreviation: 95% CI, 95% confidence interval.
aValues are expressed as mean ± SD.
tion is assessed with TOF monitoring at the adductor pol-
licis, several clinically important muscle functions may
be relatively more affected by the effect of mivacurium in
males than females when TOF ratio is similar in both gen-
ders. This fact may make males potentially more vulner-
able to the occurrence of postoperative airway and pul-
monary function-related complications when adequacy of
neuromuscular function is judged by standard TOF ratio
monitoring (i.e. at the adductor pollicis). Further studies
are needed to confirm this assumption. At present, it is
unknown if similar gender-related differences exist when
TOF-monitoring is performed at other muscles than the ad-
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ductor pollicis.
5.4. Study Limitations
Because the current study subjects were awake, the re-
searchers employed submaximal nerve stimulation dur-
ing the experiments. If not conducted with care, submax-
imal nerve stimulation may introduce erroneous results
from AP TOF ratio monitoring (5). It is believed that the
TOF ratio data are valid because the researchers always
ensured that the stimulating current was > 15 mA above
threshold for detecting the twitch response (5), and be-
cause they waited until the TOF ratio settled at a stable
value. The assumption that stable neuromuscular blocks
were obtained is supported by similar plasma concentra-
tions of mivacurium in duplicate measurements at each
block level. The observation that AP TOF ratio recovered to
baseline value in all volunteers after termination of the mi-
vacurium infusion also suggests valid recordings.
The researchers decided to use mivacurium in their
experiments due to its rapid clearance from the blood
stream, which enabled them to establish stable neuro-
muscular blocks, much faster than would have been the
case with alternative longer-acting drugs (rocuronium or
cisatracurium). At present, there is no reason to believe
that the results would have become different, had alterna-
tive neuromuscular blocking drugs been used. However,
this assumption must be verified in future studies.
5.5. Conclusions
This research demonstrated that in males, but not in
females, a significant difference in sensitivity to mivac-
urium exists between the adductor pollicis and the hand-
grip muscles. This finding explains the previous observa-
tion that men lose more handgrip strength than women
with decreasing AP TOF ratio.
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